Ashwin Kumar

Ashwin Kumar

Auto-generated profile, based on publicly available information

Ashwin Kumar

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in CJC Open
Verified
Journal Article
Open access
SMSarah E. Mudra
Sarah E. Mudra
DRDanny Rayes
Danny Rayes
AKAshwin K. Kumar
Ashwin K. Kumar
JLJason Z. Li
Jason Z. Li
MNMeredith Njus
Meredith Njus
AKAllan L. Klein
Allan L. Klein
Malignant pericardial effusion (Eff) is often asymptomatic and has an unknown prevalence, due to its occult presentation. The condition often is identified postmortem on autopsy, and it is associated with a poor prognosis. Given the late presentation of malignant pericardial Effs, a minimal volume of literature has examined the epidemiology, clinical characteristics, and outcomes of these complex patients. We conducted a systematic review to advance present understanding of this condition. A search of 4 databases resulted in 41 case reports meeting criteria. Inclusion criteria were being a patient aged > 18 years who presented with pericardial Eff in the setting of malignancy. Intervention was medical and/or surgical therapy, and the outcome was mortality. For the 41 patients included, the median age was 54 years, and the majority were male patients (58%). Dyspnea was the leading symptom (90%), and cardiac tamponade was present in 78% of cases. Common cancers included lung, gastrointestinal, and renal neoplasms (59%). Pericardiocentesis occurred in 98% of cases, with a median fluid extraction volume of 1000 mL. Death occurred in 44%, primarily due to disease progression and/or metastasis. This study presents the largest systematic review on malignancy-induced pericardial Effs to date. Notably, solid tumours, and specifically lung adenocarcinomas, are common culprits. Malignant pericardial Effs are often severe, with a majority of patients presenting with cardiac tamponade. Overall, treatment options are limited, and the associated mortality rate is high.

26 January 2023 in Heart
Verified
Journal Article
Open access
PDF file
BVBeni Verma
Beni Verma
AKAshwin Kumar
Ashwin Kumar
NVNikita Verma
Nikita Verma
AAAnkit Agrawal
Ankit Agrawal
AYAbdullah Yesilyaprak
Abdullah Yesilyaprak
AKAllan L Klein
Allan L Klein
Objective Chylopericardium (CPE) is a rare condition associated with accumulation of triglyceride-rich chylous fluid in the pericardial cavity. Due to minimal information on CPE within the literature, we conducted a systematic review of all published CPE cases to understand its clinical characteristics, management and outcomes. Methods We performed a literature search and identified cases of patients with CPE from 1946 until May 2021 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We identified relevant articles for pooled analyses of clinical, diagnostic and outcome data. Results A total of 95 articles with 98 patients were identified. Patient demographics demonstrated male predominance (55%), with a mean age of 37±15 years. Time from symptom onset to diagnosis was 5 (Q1 4.5, Q3 14) days, with 74% of patients symptomatic on presentation. Idiopathic CPE (60%) was the most common aetiology. Cardiac tamponade secondary to CPE was seen in 38% of cases. Pericardial fluid analysis was required in 94% of cases. Lymphangiography identified the leakage site in 59% of patients. Medical therapy (total parenteral nutrition, medium-chain triglycerides or octreotide) was undertaken in 63% of cases. In our cohort, 32% progressed towards surgical intervention. During a median follow-up of 180 (Q1 180, Q3 377) days, CPE recurred in 16% of cases. Of the patients with recurrence, 10% were rehospitalised. Conclusion CPE tends to develop in younger patients and may cause serious complications. Many patients fail medical therapy, thereby requiring surgical intervention. Although overall mortality is low, associated morbidities warrant close follow-up and possible reintervention and hospitalisations.

2 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
DHDiarmaid Hughes
Diarmaid Hughes
AAAli Aminian
Ali Aminian
CTChao Tu
Chao Tu
YOYuichiro Okushi
Yuichiro Okushi
YSYoshihito Saijo
Yoshihito Saijo
BXBo Xu
Bo Xu
Background: Obesity leads to an increased risk of cardiovascular disease morbidity and death, including heart failure. Bariatric surgery has been proven to be the most effective long‐term weight management treatment. This study investigated the changes in cardiac structure and function after bariatric surgery, including left ventricular global longitudinal strain. Methods and Results: There were 398 consecutive patients who underwent bariatric surgery with pre‐ and postoperative transthoracic echocardiographic imaging at a US health system between 2004 and 2019. We compared cardiovascular risk factors and echocardiographic parameters between baseline and follow‐up at least 6 months postoperatively. Along with decreases in weight postoperatively, there were significant improvements in cardiovascular risk factors, including reduction in systolic blood pressure levels from 132 mm Hg (25th–75th percentile: 120–148 mm Hg) to 127 mm Hg (115–140 mm Hg; P =0.003), glycated hemoglobin levels from 6.5% (5.9%–7.6%) to 5.7% (5.4%–6.3%; P <0.001), and low‐density lipoprotein levels from 97 mg/dL (74–121 mg/dL) to 86 mg/dL (63–106 mg/dL; P <0.001). Left ventricular mass decreased from 205 g (165–261 g) to 190 g (151–236 g; P <0.001), left ventricular ejection fraction increased from 58% (55%–61%) to 60% (55%–64%; P <0.001), and left ventricular global longitudinal strain improved from −15.7% (−14.3% to −17.5%) to −18.6% (−16.0% to −20.3%; P <0.001) postoperatively. Conclusions: This study has shown the long‐term impact of bariatric surgery on cardiac structure and function, with reductions in left ventricular mass and improvement in left ventricular global longitudinal strain. These findings support the cardiovascular benefits of bariatric surgery.

11 September 2023 in Echocardiography
Verified
Journal Article
Open access
FBFelix Berglund
Felix Berglund
AAAmbreen Ali
Ambreen Ali
PSParvathy Sankar
Parvathy Sankar
RKRehan Karmali
Rehan Karmali
MMMuhammad Majid
Muhammad Majid
AKAllan L. Klein
Allan L. Klein
A 46-year-old woman underwent pericardiocentesis and pericardial window for recurrent pericardial effusion. She presented 17 months later with signs and symptoms consistent with constrictive pericarditis. Cardiac magnetic resonance imaging revealed an infiltrative mass surrounding the pericardium. A transcutaneous core needle biopsy of the pericardium confirmed the diagnosis of pericardial mesothelioma.

11 January 2022 in CASE
Verified
Journal Article
Open access
GMGauranga Mahalwar
Gauranga Mahalwar
NBNishad Barve
Nishad Barve
MFMuhammad M. Furqan
Muhammad M. Furqan
RRReza M. Reyaldeen
Reza M. Reyaldeen
AKAshwin Kumar
Ashwin Kumar
AKAllan L. Klein
Allan L. Klein
• Metastatic GCTs may initially present as right heart failure. • TTE and TEE can diagnose cardiac metastasis and monitor cardiac function. • Multimodality imaging informs about tumor burden in metastatic cardiac tumors.

20 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
AAAnkit Agrawal
Ankit Agrawal
ARAkiva Rosenzveig
Akiva Rosenzveig
ASAhmad Safdar
Ahmad Safdar
DNDanial Nasif
Danial Nasif
UBUmesh Bhagat
Umesh Bhagat
AKAllan L. Klein
Allan L. Klein
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry a risk of immune‐related adverse events, reported in 15% to 90% of the patients. ICI‐associated pericardial and myocardial disease has been increasingly recognized, yet data on outcomes remain limited. We aimed to use a large real‐world database to investigate the short‐ and long‐term outcomes of ICI‐associated pericarditis, myocarditis, and myopericarditis versus the non‐ICI cases. Methods: We conducted a retrospective analysis using the TriNetX database to identify patients >18 years old on ICI and diagnosed with pericarditis, myocarditis, or myopericarditis within 1 year of initiation of therapy. The primary outcome assessed was all‐cause mortality, tamponade, constrictive pericarditis, and need for pericardiocentesis at 90‐day, 1‐year, and 5‐year follow‐up. Results: A total of 3661, 226, and 46 patients were identified in matched cohorts of ICI‐induced pericarditis, myocarditis, and myopericarditis, respectively. One‐ and 5‐year mortality was greater for pericarditis (44.3% versus 37.3%; 54.3% versus 46.9%), myocarditis (38.9% versus 20.8%; 47.8% versus 34.3%), and myopericarditis (56.5% versus 28.3%; 63.0% versus 28.3%; all P ≤0.002). A multivariable Cox model showed increased ICI‐related mortality for pericarditis 1‐year hazard ratio [HR], 1.20 (95% CI, 1.12–1.29), 5‐year HR, 1.26 (95% CI, 1.18–1.35), myocarditis 90‐day HR, 1.82 (95% CI, 1.21–2.73), 1‐year HR, 2.04 (95% CI, 1.43–2.91), 5‐year HR, 1.64 (95% CI, 1.26–2.61), and myopericarditis 1‐year HR, 2.24 (95% CI, 1.15–4.37), and 5‐year HR, 2.78 (95% CI, 1.44–5.36), all with P <0.001. Conclusion: Among 3661, 226, and 46 patients with ICI‐associated pericarditis, myocarditis, and myopericarditis, respectively, we demonstrated an increased risk of all‐cause mortality as compared with the respective non‐ICI population.